Greenville, South Carolina CCOP

位于南卡罗来纳州格林维尔的CCOP的长期目标包括：1)与格林维尔医院系统（GHS）重新建立统一的合作研究。2)在整个南卡罗来纳州北部，癌症预防和控制的推广和沟通能力得到巩固。3)增加与血液恶性肿瘤科学相关的辅助研究的参与。4)通过我们新开发的外科肿瘤学专业知识提供的潜在创新外科技术，扩大我们的CCOP能力。5)进一步发展持续的CCOP治理，改进质量控制。6)参与nci支持的干细胞移植研究。虽然在我们成立的最初几年里，受让方和全球卫生系统之间的政治动荡一直是我们的特点，但最近的事态发展使我们有理由相信，现在有可能采取统一的努力，为这个社区及其患者带来很大的利益。我们将努力保持这一势头。CCOP与本县两家主要医院之间的这种程度的效用和合作肯定会转化为癌症控制和预防工作的改进。随着这一领域的发展，医疗专业知识和能力的多样性也在发展。以前超出我们研究范围的研究现在是可行的。随着我们的成熟，我们觉得我们可以超越三期试验，为这个人群提供更多的东西。过去五年我们成长的烦恼已经成为了他们的工具。我们的主要优先工作是患者的累积和及时，准确的数据提交。我们现在充满希望，因为我们已经达到了成熟和稳定的程度，我们将微调组织的治理，以包括质量保证计划的发展，包括我们必须努力实现的质量指标和参数。

The Greenville, South Carolina, CCOP has long-term objectives that include: 1) Re-establishing a unified and cooperative research effort with the Greenville Hospital System (GHS). 2) Solidification of cancer prevention and control outreach and communication throughput throughout the Upstate of South Carolina. 3) Increasing participation in ancillary studies associated with the science of hematologic malignancies. 4) Expansion of our CCOP capabilities associated with potentially innovative surgical techniques offered by our newly developed surgical oncology expertise. 5) Further development of a sustaining CCOP governance with improvement in quality control. 6) Participation in NCI-supported stem cell transplant research. While the initial years of our existence have been marked by political turmoil between the grantee and GHS, there are recent developments that give us cause to believe that a unified effort is now possible much to the gain of this community and it patients. We will work diligently to make certain that the momentum is maintained. This degree of utility and cooperation between the CCOP and the two major hospitals in this county will most certainly translate into an improved cancer control and prevention effort. As this area has grown, so too has the medical expertise and diversity of capabilities and diversity of capabilities. Studies that had before been beyond our research are now feasible. As we have matured, we feel that we can move beyond Phase III trials and offer this population something more. The growing pains of the last five years of our existence have taken their tool. Our major prioritized effort was that of patient accrual and timely, accurate data submission. We are now hopeful, as we have reached a degree of maturity and stability, that we will fine-tune the governance of the organization to include the development of a quality assurance program inclusive of quality indicators and parameters we must strive to achieve.